Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nächster Kursturbo?: 226 % Plus seit Januar - wie weit kann diese Aktie noch steigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
289 Leser
Artikel bewerten:
(1)

DelveInsight Business Research, LLP: Insulin Delivery Devices Market is Projected to Grow at a CAGR of 9.23% and is also Expected to Extend Upto USD 24.13 Billion by 2026, Asserts DelveInsight

The Insulin Delivery Devices market is increasing owing to the diabetes prevalence, the rising patient awareness regarding the ease-of-use of Insulin Delivery Devices, the improvement in patient adherence and technologically advanced products such as smart insulin pens

LAS VEGAS, Dec. 1, 2021 /PRNewswire/ -- DelveInsight's Insulin Delivery Devices Market Insights and Forecast report provides the current and forecast Insulin Delivery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Insulin Delivery Devices Market.

DelveInsight Logo

Some of the salient features from the Insulin Delivery Devices Market report:

  • As per DelveInsight analysis, in terms of revenue share, APAC is predicted to register the fastest growth in the Insulin Delivery Devices market because of the high prevalence of diabetes.
  • Major pharma players working proactively in the Insulin Delivery Devices Market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.
  • DelveInsight estimates that Global Insulin Delivery Devices Market is expected to grow at an escalated CAGR of 9.23% during the forecast period from 2021 to 2026 and is anticipated to reach USD 24.13 billion by 2026.
  • In May 2021, Medtronic plc received the CE (Conformité Européenne) Mark approval for their InPen smart insulin pen for expanded functionality as multiple daily injections (MDI).
  • In May 2021, Eli Lilly entered into agreements with four companies DexCom, Inc., Glooko Inc., myDiabby Healthcare and Roche - to advance connected solutions and streamline care for diabetic people living outside of the United States. These companies offer unique diabetes management platforms which will be compatible with Lilly's Tempo Pen (approved in several global markets) and Tempo Smart Button (currently in late-stage development).

Interested in knowing how the Insulin Delivery Devices Market will be growing by 2026? Click to get a snapshot of Insulin Delivery Devices Market Analysis

Insulin Delivery Devices Overview

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood sugar, or when the body cannot effectively use the insulin it produces. It can be classified into three main types namely, Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Among all the most common is type 2, usually affecting adults as a result when the body becomes resistant to insulin or produce insufficient insulin.

Over the years, there has been a continuous increase in the prevalence of diabetes that has been attributed to changing lifestyles in cities and rural regions, globalization, bad eating habits, particularly among teens and adults, an increase in the obese and geriatric population, and a lack of daily physical activities.

To pick on the latest highlights related to Insulin Delivery Devices, get the snapshot of the key highlights entailed in the Insulin Delivery Devices Market report.

Insulin Delivery Devices Market Insight

In 2021, the discovery of insulin will mark 100 years, as the origin of diabetes therapy dates back to the 1920s with the discovery of insulin and its applications. The Insulin Delivery Devices started with the syringe and moved to insulin pens, insulin pumps, and sensor-augmented pumps.

Geographically, the global Insulin Delivery Devices market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, APAC is predicted to register the fastest growth in the Insulin Delivery Devices market because of the high prevalence of diabetes, increase in awareness regarding diabetes and its management, improving disposable income, among other factors in the region.

According to DelveInsight estimates, in the product type segment of the Insulin Delivery Devices market, insulin pens which are further sub-segmented into reusable and disposable are projected to hold the largest market among other insulin delivery devices. This is due to its long-term benefit, the reusable insulin pens appear to be more economical compared to conventional Insulin Delivery Devices.

The launch of new innovative products will lead to an increased demand for Insulin Delivery Devices, for instance, in November 2020, the French company Diabeloop, a pioneer in therapeutic AI, and Terumo Corporation signed an agreement for the joint development with exclusive distribution rights in Japan of an automated insulin delivery (AID) solution. The Diabeloop-developed system will integrate Terumo's innovative insulin patch pump.

To know more why the Asia Pacific is leading the market growth in the Insulin Delivery Devices market, get a snapshot of the report Insulin Delivery Devices market

Insulin Delivery Devices Market Drivers and Barriers

Many players in the medical device and healthcare industries are working together to create an ecosystem through technology that allows patients to manage their diabetes and receive input from doctors remotely, saving both money and time. Therefore, advancements in Insulin Delivery Devices is anticipated to boost the global Insulin Delivery Devices market. Various other factors such as the immensely high prevalence of Diabetes, user-friendly design of Insulin Delivery Devices, rising popularity, adoption rate among the patient population, and the launch of new innovative products will lead to an increased demand for Insulin Delivery Devices contributing to a massive surge in Insulin Delivery Devices market.

The demand for Insulin Delivery Devices is primarily affected by the outbreak of the COVID-19 pandemic because of the delay in the supply and manufacturing of the products. However, Type 2 diabetes, hypertension, and cardiovascular diseases have been identified as the most common comorbidities for SARS-CoV-2 infection and have been associated with worse outcomes and a more severe course of COVID-19.

To discuss more about the short/long-term impact of COVID-19 get a snapshot of the report Insulin Delivery Devices market

Scope of the Insulin Delivery Devices Market Report

Study Period: 2018-2026

Key Companies: Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD

Insulin Delivery Devices Market Segmentation

By Product Type

  • Insulin Syringes
  • Insulin Pens
    • Reusable
    • Disposable
  • Insulin Pumps
    • Tethered/External Pumps
    • Patch Pumps
  • Insulin Injectors
  • Others

By End-User

  • Hospitals
  • Homecare Settings
  • Diabetes Centres
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Delveinsight Analysis: The Insulin Delivery Devices market is expected to grow at a CAGR of 9.23% during the forecast period from 2021 to 2026, to reach USD 24.13 billion by 2026.

Table of Contents

1

Insulin Delivery Devices Market Report Introduction

2

Insulin Delivery Devices Market Executive summary

3

Regulatory and Patent Analysis

4

Insulin Delivery Devices Market Key factors analysis

5

Insulin Delivery Devices Porter's Five Forces Analysis

6

COVID-19 Impact Analysis on Insulin Delivery Devices Market

7

Insulin Delivery Devices Market Layout

8

Insulin Delivery DevicesGlobal Company Share Analysis - Key 3-5 Companies

9

Insulin Delivery Devices Market Company and Product Profiles


9.1 Medtronic

9.2 Abbott

9.3 BD

9.4 Terumo Group

9.5 Eli Lilly and Company

9.6 F. Hoffmann-La Roche Ltd.

9.7 Insulet Corporation

9.8 BIGFOOT BIOMEDICAL, INC

9.9 Novo Nordisk A/S

9.10 Sanofi

9.11 Roche

9.12 Emperra GmbH E-Health Technologies

9.13 Copernicus (Nemera)

9.14 ARKRAY USA, Inc

9.15 Ypsomed AG

9.16 HTL-Strefa (MTD Medical Technology and Devices S.A)

9.17 Trividia Health Inc

9.18 Biocon

9.19 EOFLOW CO., LTD.

9.20 SUNGSHIM MEDICAL CO., LTD.

10

Project Approach

11

KOL Views

12

DelveInsight Capabilities

13

Disclaimer

14

About DelveInsight

Learn more about the report offerings @ Insulin Delivery Devices Market Outlook

Understand the Competition, Risk Assessment and effective Research and Development approach to take value-based decisions.

Related Reports

Diabetes Pen Market

DelveInsight's 'Diabetes Pen- Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Diabetes Pen and the historical and forecasted Diabetes Pen market trends, market drivers, market barriers and key companies involved such as AstraZeneca, Teruma Medical Corporation, Greinier Bio One International GmBH, F. Hoffman La Roche AG, Becton, Dickinson and Company Bayer Cropscience Ltd, HTL STREFA SA, and others.

Injectable Drug Delivery Devices Market

Global Injectable Drug Delivery Devices Market was valued at USD 17.65 billion in 2020, growing at a CAGR of 11.25% during the forecast period from 2021 to 2026, to reach USD 33.37 billion by 2026. The report delivers an in-depth understanding of Injectable Drug Delivery Devices and the historical and forecasted market trends, market drivers, market barriers and key companies involved such as Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Johnson & Johnson, Antares Pharma, AbbVie Inc, Pfizer Inc, Mylan N.V. and others.

Catheter-Related Bloodstream Infection Market

DelveInsight's 'Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the catheter-related bloodstream infection, historical and forecasted epidemiology as well as key companies involved in pipelines such as CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and others.

Smart Insulin Pens Market

DelveInsight's 'Smart Insulin Pens Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of Smart Insulin Pens and the historical and forecasted Smart Insulin Pens market trends, market drivers, market barriers and key companies involved such as Novo Nordisk, DiabNext, InsulCloud, Medtronic, Companion Medical, Biocorp, Bigfoot Medical, Emperra GmbH E-Health Technologies, and others.

Implantable Infusion Pump Market

The demand for an Implantable Infusion Pump is primarily associated with the growing prevalence of various disorders such as diabetes, cancer, chronic pain, and various other disorders among the population coupled with the growing burden of the old age population. DelveInsight's 'Implantable Infusion Pump - Market Insight, Competitive Landscape and Market Forecast, 2026' provides details about historical and forecasted Implantable Infusion Pump market trends, market drivers and barriers, and key companies involved such as Medtronic, Intera Oncology, FLOWONIX MEDICAL INC, Tandem Diabetes Care, Inc., and many others.

Drug Infusion System - Market

"DelveInsight's 'Drug Infusion System - Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Drug Infusion System and the historical and forecasted Drug Infusion System market trends, market drivers and barriers, and key companies involved such as Medtronic, B. Braun Melsungen AG, Baxter, Arcomed AG, Halyard Health, INC, ICU Medical Inc, Insulet Corporation, Terumo Corporation, Smiths Group Plc, Tandem Diabetes Care, and many others.

Browse Through Our Blog Posts

  • Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation
  • Evolution in Diabetes Management
  • Cost-effectiveness, Advanced Technology, Rising Demand Pushes the Insulin Delivery Devices Market
  • Which Companies are Vying to get a Major Chunk in the Elastomeric Pump Market?

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

© 2021 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.